<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941391</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-16-EU</org_study_id>
    <nct_id>NCT04941391</nct_id>
  </id_info>
  <brief_title>AcQBlate Force Sensing Ablation System EU Study for Atrial Fibrillation</brief_title>
  <acronym>AcQForce AF-EU</acronym>
  <official_title>AcQBlate Force Sensing Ablation System EU Study for Atrial Fibrillation (AcQForce AF-EU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acutus Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acutus Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AcQForce AF-EU clinical study is a prospective, multi-center, non-randomized global&#xD;
      clinical study designed to demonstrate the safety and performance of the AcQBlate Force&#xD;
      Sensing System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The AcQForce AF-EU clinical study is a prospective, multi-center, non-randomized global&#xD;
      clinical study designed to demonstrate the safety and performance of the AcQBlate Force&#xD;
      Sensing System. The AcQForce AF-EU study is a post-market study that will be run in parallel&#xD;
      with a US IDE study of similar design. Data will be combined to support a pre-market approval&#xD;
      (PMA) application to the US Food and Drug Administration (FDA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two distinct, non-randomized cohorts of subjects will be included; a PAF population and a PerAF population</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who are free from device and/or procedure related Major Adverse Events (MAEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Subjects free from a composite list of pre-specified procedure/device related Major</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects demonstrating freedom from AF/AT/AFL following a blanking period</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from recurrence of atrial arrhythmias</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recording and analysis of all identified serious adverse events/device effects</measure>
    <time_frame>12 months</time_frame>
    <description>Recording of all serious adverse events/device effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Paroxysmal atrial fibrillation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects schedule for a de novo ablation of paroxysmal atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Persistent atrial fibrillation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects schedule for a de novo ablation of persistent atrial fibrillation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcQBlateÂ® Force Sensing Ablation System</intervention_name>
    <description>Catheter ablation of accessible pulmonary veins with the endpoint of creating electrical isolation for each targeted vein. Additional left and right atrial targets may be ablated as clinically indicated.</description>
    <arm_group_label>Paroxysmal atrial fibrillation</arm_group_label>
    <arm_group_label>Persistent atrial fibrillation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female between the ages of 18 to 80 years at time of consent&#xD;
&#xD;
          2. Clinically indicated and scheduled for a de novo catheter ablation of symptomatic PAF&#xD;
             or PerAF.&#xD;
&#xD;
          3. Refractory to Antiarrhythmic Drug (AAD) treatment&#xD;
&#xD;
          4. Willing and able to provide written informed consent to participate in the study and&#xD;
             agree to comply with all follow-up visits and evaluations for the duration of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In the opinion of the investigator, any contraindication to the planned atrial&#xD;
             ablation, including anticoagulation contraindications or sepsis.&#xD;
&#xD;
          2. Continuous episodes of AF Duration:&#xD;
&#xD;
               1. PAF: AF duration lasting longer than 7 days&#xD;
&#xD;
               2. Persistent AF: AF duration lasting longer than 12-months.&#xD;
&#xD;
          3. Atrial arrhythmias secondary to electrolyte imbalance, thyroid disease, or any other&#xD;
             reversible or non-cardiac cause.&#xD;
&#xD;
          4. An implantable cardiac defibrillator (ICD) or pacemaker.&#xD;
&#xD;
          5. Previous history of left atrial ablation (including surgical treatment) for AF/AT/AFL.&#xD;
&#xD;
          6. Structural heart disease or cardiac history as described below:&#xD;
&#xD;
               1. Left ventricular ejection fraction (LVEF) &lt; 40% based on transthoracic&#xD;
                  echocardiogram (TTE) within the previous 180-days.&#xD;
&#xD;
               2. Left atrial size &gt; 55 mm based on transthoracic echocardiogram (TTE) measurement&#xD;
                  of the anteroposterior diameter, parasternal long-axis view in M Mode and&#xD;
                  performed within the previous 180-days.&#xD;
&#xD;
               3. Evidence of heart failure (NYHA Class III or IV)&#xD;
&#xD;
               4. Previous cardiac surgery, ventriculotomy, or atriotomy (excluding atriotomy for&#xD;
                  coronary artery bypass).&#xD;
&#xD;
               5. Previous cardiac valvular surgical or percutaneous procedure, or prosthetic&#xD;
                  valve.&#xD;
&#xD;
               6. Coronary artery bypass graft (CABG) within the last 180-days or coronary&#xD;
                  angioplasty (PTCA) procedure within the last 90-days.&#xD;
&#xD;
               7. Unstable angina or ongoing myocardial ischemia.&#xD;
&#xD;
               8. Myocardial infarction within the previous 180-days (sub-endocardial infarct&#xD;
                  within previous 90-days).&#xD;
&#xD;
               9. Severe uncontrolled systemic hypertension (systolic pressure &gt; 240 mm Hg,&#xD;
                  diastolic pressure &gt; 140 mm Hg) recorded within the last 30 days.&#xD;
&#xD;
              10. Moderate or severe valvular heart disease (stenosis or regurgitation).&#xD;
&#xD;
              11. Interatrial baffle, closure device, patch, or patent foramen ovale (PFO)&#xD;
                  occluder.&#xD;
&#xD;
              12. Presence of a left atrial appendage occlusion device.&#xD;
&#xD;
              13. Previous PV stenting or evidence of PV stenosis.&#xD;
&#xD;
          7. Presence of Left Atrial Thrombus&#xD;
&#xD;
          8. Body Mass Index (BMI) &gt; 42 kg/m2&#xD;
&#xD;
          9. Estimated Glomerular Filtration Rate (eGFR) of &lt;40 mL/min/1.73 m2 (by Modification of&#xD;
             Diet in Renal Disease formula)&#xD;
&#xD;
         10. History of blood clotting or bleeding disease.&#xD;
&#xD;
         11. ANY prior history of documented cerebral infarct, or systemic embolism (excluding&#xD;
             post-operative deep vein thrombosis (DVT)).&#xD;
&#xD;
         12. History of chronic obstructive pulmonary disease (COPD) requiring oral or IV steroid&#xD;
             use in the previous 12-months.&#xD;
&#xD;
         13. History of obstructive sleep apnea not currently being treated.&#xD;
&#xD;
         14. Pregnant or lactating (current or anticipated during study follow-up).&#xD;
&#xD;
         15. Current enrollment in any other study protocol where testing or results from that&#xD;
             study may interfere with the procedure or outcome measurements for this study.&#xD;
&#xD;
         16. Any other condition that, in the judgment of the Investigator, makes the patient a&#xD;
             poor candidate for this procedure, the study or compliance with the protocol (includes&#xD;
             vulnerable patient population, mental illness, addictive disease, terminal illness&#xD;
             with a life expectancy of less than two years, extensive travel away from the research&#xD;
             center).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Craig Dull, MS</last_name>
    <phone>442-232-6080</phone>
    <email>craig.dull@acutus.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jerald L. Cox, PA</last_name>
    <phone>760-529-6310</phone>
    <email>jerry.cox@actus.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paroxysmal Atrial Fibrillation</keyword>
  <keyword>Persistent Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

